Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503668 · ClinicalTrials.gov registry record · Phase 3
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
A Phase 3 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT04503668: Clinical Trial Phase 3 study, sponsored by University of Michigan Rogel Cancer Center.
NCT04503668 is a Phase 3 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 62 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04503668, a Phase 3 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.
Primary Outcome
Complete response (CR) is defined as no episodes of vomiting and no use of rescue antiemetic medications. Patient reported diaries will be used to measure this outcome.
Interventions
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Olanzapine
- DRUG Neurokinin-1 Receptor Antagonist (NK1-RA)
- DRUG Compazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 3 |
Why NCT04503668 stopped before completion
NCT04503668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT04503668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04503668 about?
NCT04503668 is a clinical study titled "Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients". The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin...
What is the current status of trial NCT04503668?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2020-12-28. Estimated completion is 2024-03-11.
What interventions are being tested in trial NCT04503668?
The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG), Olanzapine (DRUG), Neurokinin-1 Receptor Antagonist (NK1-RA) (DRUG), Compazine (DRUG).
Who is sponsoring clinical trial NCT04503668?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04503668's enrollment target sits among peer trials
62 1802nd of 2000 higher than 198 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI